HK1083492A1 - Substituted piperazine compounds and their use as fatty acid oxidation inhibitors - Google Patents

Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Info

Publication number
HK1083492A1
HK1083492A1 HK06102183A HK06102183A HK1083492A1 HK 1083492 A1 HK1083492 A1 HK 1083492A1 HK 06102183 A HK06102183 A HK 06102183A HK 06102183 A HK06102183 A HK 06102183A HK 1083492 A1 HK1083492 A1 HK 1083492A1
Authority
HK
Hong Kong
Prior art keywords
fatty acid
acid oxidation
oxidation inhibitors
substituted piperazine
piperazine compounds
Prior art date
Application number
HK06102183A
Other languages
English (en)
Inventor
Elfatih Elzein
Dmitry Koltun
Jeff Zablocki
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of HK1083492A1 publication Critical patent/HK1083492A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK06102183A 2002-12-05 2006-02-17 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors HK1083492A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43150602P 2002-12-05 2002-12-05
PCT/US2003/038867 WO2004052887A2 (en) 2002-12-05 2003-12-05 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Publications (1)

Publication Number Publication Date
HK1083492A1 true HK1083492A1 (en) 2006-07-07

Family

ID=32507739

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06102183A HK1083492A1 (en) 2002-12-05 2006-02-17 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
HK08100361.3A HK1111683A1 (en) 2002-12-05 2008-01-10 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK08100361.3A HK1111683A1 (en) 2002-12-05 2008-01-10 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Country Status (12)

Country Link
US (2) US7125876B2 (ko)
EP (1) EP1567525B1 (ko)
JP (1) JP2006510670A (ko)
KR (1) KR20050084182A (ko)
AT (1) ATE365737T1 (ko)
AU (1) AU2003300827B2 (ko)
CA (1) CA2508608A1 (ko)
DE (2) DE60314662T2 (ko)
ES (2) ES2287574T3 (ko)
HK (2) HK1083492A1 (ko)
NZ (1) NZ540548A (ko)
WO (1) WO2004052887A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063180A1 (en) * 2003-01-03 2004-07-29 Cv Therapeutics, Inc. Substituted heterocyclic compounds
WO2006029179A2 (en) * 2004-09-08 2006-03-16 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
US20070155727A1 (en) * 2005-12-29 2007-07-05 Schering Aktiengessellschaft Amide inhibitors of leukotriene A4 hydrolase
KR101476379B1 (ko) 2011-11-30 2014-12-29 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2267104A1 (en) * 1974-04-12 1975-11-07 Ferlux Labo Sa Hypotensive and antiarrhythmic piperazines - 1-(3-phenoxy-2-hydroxy propyl)-4-substd. piperazines
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4558129A (en) 1983-05-18 1985-12-10 Syntex (U.S.A.) Inc. Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US4588129A (en) * 1983-09-06 1986-05-13 Hudson Oxygen Therapy Sales Company Nebulizer
US4788306A (en) * 1987-04-03 1988-11-29 American Home Products Corporation Fluorooxirane carboxylates as hypoglycemic agents
JPH0730456Y2 (ja) 1989-05-11 1995-07-12 株式会社神戸製鋼所 ホイールクレーンのステアリング制御装置
EP0407780B1 (en) * 1989-06-23 1996-09-11 Syntex (U.S.A.) Inc. Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
CZ297451B6 (cs) * 1997-05-26 2006-12-13 Kowa Company, Ltd. Derivát cyklického diaminu, jeho pouzití a farmaceutický prostredek, který ho obsahuje
EP2033633A3 (en) * 2000-02-18 2009-07-08 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6451798B2 (en) * 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
AU2001238590A1 (en) * 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
IL151178A0 (en) * 2000-02-22 2003-04-10 Cv Therapeutics Inc Substituted piperazine compounds
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6638970B2 (en) * 2000-02-22 2003-10-28 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6693099B2 (en) * 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
SE0003795D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
ATE292633T1 (de) * 2001-07-19 2005-04-15 Cv Therapeutics Inc Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren

Also Published As

Publication number Publication date
WO2004052887A3 (en) 2004-07-15
DE60314662T2 (de) 2008-03-13
US7125876B2 (en) 2006-10-24
AU2003300827B2 (en) 2009-08-13
US7407960B2 (en) 2008-08-05
US20040152890A1 (en) 2004-08-05
DE60328545D1 (de) 2009-09-03
HK1111683A1 (en) 2008-08-15
AU2003300827A1 (en) 2004-06-30
KR20050084182A (ko) 2005-08-26
EP1567525B1 (en) 2007-06-27
JP2006510670A (ja) 2006-03-30
CA2508608A1 (en) 2004-06-24
NZ540548A (en) 2008-03-28
WO2004052887A2 (en) 2004-06-24
ES2287574T3 (es) 2007-12-16
ATE365737T1 (de) 2007-07-15
ES2327873T3 (es) 2009-11-04
DE60314662D1 (de) 2007-08-09
EP1567525A2 (en) 2005-08-31
US20070004751A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
IL159897A0 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
NZ604478A (en) Fused heterocyclic compounds as ion channel modulators
NO20054969L (no) 2-cyanopropansyreamid- og esterderivater og deres anvendelse
CU23210A3 (es) NUEVOS COMPUESTOS DE OXABISPIDINE uTIL EN EL TRATAMIENTO DE ARRITMIAS CARDIACAS
NO20023879L (no) Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt
HK1111683A1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
BG108941A (en) Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic
SE0100326D0 (sv) New compounds
MXPA02012910A (es) Amidas de acidobifenilcarboxilico, su preparacion y su uso como medicinas.
HK1085467A1 (en) Substituted heterocyclic compounds
MXPA02006249A (es) Nuevos derivados de azabiciclooctano, utiles en el tratamiento de arritmias cardiacas.
TW200612907A (en) New compounds
WO2001062744A3 (en) Substituted piperazine compounds
YU49902A (sh) Supstituisani derivati piperazina kao mtp inhibitori
WO2004067506A3 (en) Substituted heterocyclic compounds
WO2001062711A3 (en) Substituted alkylene diamine compounds
WO2006029179A3 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
SE0003795D0 (sv) Pharmaceutically useful compounds
JP2007514769A5 (ko)
AR024393A1 (es) Nuevos compuestos de bispidina para usar en el tratamiento de las arritmias cardiacas.
DE60336549D1 (de) Hepatoprotektor aktivität von 2'-p-hydroxybenzoylmussaenosidsäure
ATE474584T1 (de) Verwendung von cis-rhenium (iii) diadamantat- verbindungen zur verstärkung der antitumoralen wirkung von platinkomplexen
ATE409221T1 (de) Acylglycerin-acyltransferase-ähnliches protein mgat-x1 und verwendungen davon

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111205